Agree Gary and this raises a key issue.
If murcidencel is so great, so effective, so innovative, such a game-changer, then why has a scientific abstract never been presented at ASCO?
This is where I sense that NWBO's top management (strong on law, weak on medicine) is out of touch with the clinical oncology community. Trust me, there are plenty of medical oncologists out there who would do handsprings if they knew there was a safe and effective treatment for glioblastoma available that beats the current standard of care. These same physicians would listen with rapt attention if such an abstract were presented at a major medical meeting like ASCO. And many ASCO members might agree that murcidencel deserves high marks, maybe even top rank, in a contest among the most important breakthroughs in cancer treatment in a given year.
But for some reason NWBO hasn't seen fit to pursue this approach. Instead, they've been content to promote the product in an investor-friendly (but scientifically suspect) forum such as the ASCO product theater. In so doing I fear they've shot themselves in the foot with investors in the long term because they've diminished their credibility with the people who matter most to the company's bottom line: prescribers.
(I realize Linda Liau's scientific presentation at SNO in Florida several months ago weakens my argument. So do Dr. Mulholland's talk at NYAS last May, and Dr. Ashkan's recent presentations at medical conferences in the UK. But I remain dissatisfied with the way the company has handled its relationship with ASCO, which after all is the largest and most important association of clinical oncologists, certainly in the United States and perhaps the world.)
-- OJ
Market Data 
Markets 
AI
